代香萍, 薛磊, 许倩文, 胡艳, 陈元禄, 王兴兵. 手术方式对原发中枢神经系统淋巴瘤患者疗效和安全性的影响[J]. 中国肿瘤临床, 2024, 51(8): 413-417. DOI: 10.12354/j.issn.1000-8179.2024.20240242
引用本文: 代香萍, 薛磊, 许倩文, 胡艳, 陈元禄, 王兴兵. 手术方式对原发中枢神经系统淋巴瘤患者疗效和安全性的影响[J]. 中国肿瘤临床, 2024, 51(8): 413-417. DOI: 10.12354/j.issn.1000-8179.2024.20240242
Xiangping Dai, Lei Xue, Qianwen Xu, Yan Hu, Yuanlu Chen, Xingbing Wang. Impact of surgical approach on the efficacy and safety of patients with primary central nervous system lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 51(8): 413-417. DOI: 10.12354/j.issn.1000-8179.2024.20240242
Citation: Xiangping Dai, Lei Xue, Qianwen Xu, Yan Hu, Yuanlu Chen, Xingbing Wang. Impact of surgical approach on the efficacy and safety of patients with primary central nervous system lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 51(8): 413-417. DOI: 10.12354/j.issn.1000-8179.2024.20240242

手术方式对原发中枢神经系统淋巴瘤患者疗效和安全性的影响

Impact of surgical approach on the efficacy and safety of patients with primary central nervous system lymphoma

  • 摘要:
    目的 探讨不同手术方式对原发中枢神经系统淋巴瘤(primary central nervous system lymphoma,PCNSL)患者疗效和安全性的影响。
    方法 回顾性分析2012年7月至2023年5月中国科学技术大学附属第一医院(安徽省立医院)收治的130例PCNSL患者的临床资料,根据手术方式分为切除组和活检组,比较两组的安全性及疗效,包括化疗后的客观缓解率(objective response rate,ORR)、总生存期(overall survival,OS)和无进展生存期(progression-free survival,PFS)。
    结果 切除组的ORR、2年OS率、2年PFS率与活检组比较无统计学差异(ORR:63.2% vs. 62.8%;2年OS率:68.6% vs. 73.7%;2年PFS率:35.2% vs. 40.7%,P>0.05),切除组的术后并发症发生率高于活检组(29.3% vs. 11.4%,P=0.04)。两组住院时间无统计学差异,但活检组费用较少(P<0.01)。
    结论  对PCNSL患者,接受活检和切除的疗效相当,但与切除相比,活检的安全性较好,且住院费用更少。

     

    Abstract:
    Objective To investigate the effects of different surgical approaches on the efficacy and safety of patients with primary central nervous system lymphoma (PCNSL).
    Methods The clinical data of 130 PCNSL patients admitted to The First Affiliated Hospital of University of Science and Tecnology of China between July 2012 and May 2023 were retrospectively analyzed. Patients were assigned into resection and biopsy groups according to the surgical approach. The safety and efficacy of the two groups were compared, including the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) after chemotherapy.
    Results ORR and 2-year OS and PFS rates of the resection group were not significantly different from those of the biopsy group (ORR: 63.2% vs. 62.8%; 2-year OS rate: 68.6% vs. 73.7%; 2-year PFS rate: 35.2% vs. 40.7%, all P>0.05). The incidence of postoperative complications was significantly higher in the resection group than in the biopsy group (29.3% vs. 11.4%, P=0.04). The difference in the length of hospitalization between the two groups was not statistically significant. Treatment of the biopsy group was less expensive (P<0.01).
    Conclusions In patients with PCNSL, biopsy and resection had comparable efficacy; however, the safety profile was better, and hospitalization was less costly in biopsy than in resection.

     

/

返回文章
返回